[{"id":"34b87302-7697-4b60-8b03-5b5bf404028e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03889275","created_at":"2021-01-18T19:09:59.243Z","updated_at":"2024-07-02T16:35:55.143Z","phase":"Phase 1","brief_title":"A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors","source_id_and_acronym":"NCT03889275","lead_sponsor":"MedImmune LLC","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • MEDI5395"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 11/19/2021","primary_completion_date":" 11/19/2021","study_txt":" Completion: 12/12/2022","study_completion_date":" 12/12/2022","last_update_posted":"2023-02-20"}]